• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (31)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Corneal Disorders  • Randomized Controlled Trial  • Articles for Residents  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Results of a Prospective, Open-Label, Noncomparative Study

Mohammad H. Dastjerdi, MD; Khalid M. Al-Arfaj, MD; Nambi Nallasamy, BA; Pedram Hamrah, MD; Ula V. Jurkunas, MD; Roberto Pineda II, MD; Deborah Pavan-Langston, MD; Reza Dana, MD, MSc, MPH

Arch Ophthalmol. 2009;127(4):381-389.

Objective  To study the safety and efficacy of topical bevacizumab in the treatment of corneal neovascularization (NV).

Design  In a prospective, open-label, noncomparative study, 10 eyes from 10 patients with stable corneal NV were treated with topical bevacizumab, 1.0%, for 3 weeks and followed up for up to 24 weeks.

Main Outcome Measures  The primary safety variables were the occurrence of ocular and systemic adverse events throughout the course of the study. The primary efficacy variables were neovascular area, the area of the corneal vessels themselves; vessel caliber, the mean diameter of the corneal vessels; and invasion area, the fraction of the total corneal area covered by the vessels.

Results  From baseline visit to the last follow-up visit, mean reductions were 47.1% (standard deviation [SD], 36.7%) for neovascular area, 54.1% (SD, 28.1%) for vessel caliber, and 12.2% (SD, 42.0%) for invasion area. The decreases in neovascular area and vessel caliber were statistically significant (P = .001 and P < .001, respectively). However, changes in invasion area did not achieve statistical significance (P = .19). Visual acuity and central corneal thickness showed no significant changes. Topical bevacizumab was well tolerated with no adverse events.

Conclusions  Short-term topical bevacizumab therapy reduces the severity of corneal NV without local or systemic adverse effects.

Application to Clinical Practice  Topical bevacizumab provides an alternative therapy in the treatment of stable corneal NV.

Trial Registration  clinicaltrials.gov Identifier: NCT00559936

Author Affiliations: Cornea and Refractive Surgery Service, Massachusetts Eye and Ear Infirmary, Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable
Cursiefen et al.
Br J Ophthalmol 2012;96:3-9.
ABSTRACT | FULL TEXT  

Doxycycline Enhances the Inhibitory Effects of Bevacizumab on Corneal Neovascularization and Prevents Its Side Effects
Su et al.
IOVS 2011;52:9108-9115.
ABSTRACT | FULL TEXT  

Corneal Penetration of Topical and Subconjunctival Bevacizumab
Dastjerdi et al.
IOVS 2011;52:8718-8723.
ABSTRACT | FULL TEXT  

Evaluation of corneal neovascularisation
Faraj et al.
Br J Ophthalmol 2011;95:1343-1344.
FULL TEXT  

A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor
Chabot et al.
JEM 2011;208:973-986.
ABSTRACT | FULL TEXT  

Spontaneous Lymphatic Vessel Formation and Regression in the Murine Cornea
Zhang et al.
IOVS 2011;52:334-338.
ABSTRACT | FULL TEXT  

Effects of Topical and Subconjunctival Bevacizumab in High-Risk Corneal Transplant Survival
Dastjerdi et al.
IOVS 2010;51:2411-2417.
ABSTRACT | FULL TEXT  

Differential Distribution of Blood and Lymphatic Vessels in the Murine Cornea
Ecoiffier et al.
IOVS 2010;51:2436-2440.
ABSTRACT | FULL TEXT